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Immune tolerance mechanisms supporting normal human pregnancy are exploited by breast cancer and other
malignancies. We cloned from human placenta and breast cancer cells the novel human immunomodulator
named placenta immunosuppressive ferritin (PLIF). PLIF is composed of a ferritin heavy chain–like domain and a
novel cytokine-like domain, named C48. Both intact PLIF and C48 inhibit T cell proliferation. Blocking PLIF by
specific antibodies in a tolerant breast cancer model in nude mice resulted in tumor cell apoptosis and rejection.
This prompted us to study active immune preventive strategies targeting PLIF activity. Currently, we report on the
design and synthesis of the novel C24D polypeptide, which inhibits the binding of PLIF to T cells and therefore
inhibits the immune suppressive effect of PLIF. The effect of C24D on the generation of anti–breast cancer
cytotoxic T lymphocytes (CTLs) was studied in vitro in cultures of MCF-7 (HLA-A2+) or T47D (HLA-A2−) breast
cancer cells incubated with peripheral blood mononuclear cells (PBMCs) from healthy blood donors. We found
that C24D treatment exclusively induced development of CTLs. On reactivation by their specific target cells, the
CTLs secreted interferon-γ and induced target apoptosis. Anti–MCF-7 CTLs were cross-cytotoxic to MDA-MB-231
(HLA-A2+) triple-negative breast cancer but not to T47D. Moreover, C24D treatment in vivo inhibited the growth of
MCF-7 tumors engrafted in immune-compromised nude mice transfused with naïve allogeneic human PBMCs.
Our results demonstrate that C24D treatment breakdown breast cancer induced tolerance enabling the initiation of
effective anti-tumor immune response.
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A multitude of immunomodulatory properties of the feto-maternal
interface (placenta) has evolved to allow the survival of the
immunologic distinct fetus without an attack from the maternal
immune system. A substantial body of literature exists describing the
mechanisms used by cancer cells to escape apoptosis while evading a
host immune response. These studies have advanced the field of
cancer immunology and passive or active immunotherapy [1–6].
The similarities between the mechanisms involved in feto-maternal
and tumor-associated immunologic tolerance are intriguing and
suggest a common pattern. Our research strategy, which has spanned
the last three decades, searched for mechanisms of cancer immune
tolerance based on the parallels in proliferation and immune privilege
between cancer and pregnancy. Investigation of the similarities
between tolerogenic systems within the tumor microenvironment and
the feto-maternal interface led to fundamental clinical and experimental
milestone discoveries, listed as follows: A tumor-associated antigen that
cross-reacted with human ferritin blocked the surface of T cells and
induced immune suppression in patients with Hodgkin's disease [7]
and breast cancer [8]; the development of CM-H9 monoclonal
antibody (mAb) specific to placental and tumor-derived isoferritins that
did not react with normal human ferritin [9] enabled the discovery of
placental type isoferritin (PLF) secretion during normal human
gestation and the high correlation between low or deficient PLF and
abortions [10]. The further use of CM-H9 mAb confirmed that PLF
acted as a diagnostic biomarker for patients with early breast malignancy
[11]. Finally, we cloned the novel placenta immunosuppressive ferritin
(PLIF) gene from human placenta and from breast cancer cells and
discovered its unique expression, protein structure, and function in the
regulation of specific cell-mediated immunity [12].
PLIF is a protein composed of 165 amino acids, of which 117
match the ferritin heavy chain sequence, whereas the 48 C-terminal
amino acids (C48) represent a novel amino acid sequence. C48
exhibits the immunosuppressive bioactivity of PLIF [12]. C48-PLIF
binds to macrophages and activated T cells, inducing high levels of
interleukin-10 (IL-10), and acts as a regulatory cytokine governing
the balance between Th1 and Th2 cytokines [12–14]. During normal
pregnancy, PLIF expression is elevated as early as day 11, remains
elevated throughout gestation, and declines at term. PLIF is low in
missed abortions, early pregnancy failures, and intrauterine growth
restriction [10,15–18]. Furthermore, it is a physiological down-
regulator of cell-mediated immune reactivity during pregnancy [19,20].
Experimental neutralization of PLIF in pregnant mice by
antibodies inhibited placental and fetal growth and modulated the
cytokine network toward a TH1-type immune response [21].
PLIF is upregulated and expressed in the majority of human breast
primary tumors [22] and human breast cancer cell lines (T47D and
MCF-7) [12] but not in benign breast disease [11]. Both breast cancer
cells and syncytiotrophoblasts of the developing placenta secrete
PLIF. It creates a microenvironment supportive of immunologic
privilege and systemic alterations in immunity, particularly with
respect to a helper T cell type 2 polarization [14,16].
Experiments were performed in a mouse model to restore T cell
cytotoxic activity and reject breast cancer by neutralizing C48-PLIF
and its immunosuppressive cytokines (IL-10). We have previously
shown that blocking PLIF by anti–C48-PLIF antibodies in nude
mice engrafted with MCF-7 breast cancer cells and human peripheral
blood mononuclear cells (PBMCs) resulted in tumor regression
associated with tumor cell apoptosis. This treatment affected thecytokine network from TH2 to TH1 type, leading to the breakdown
of PLIF-induced immune tolerance [23]. It was thus demonstrated
that blocking C48-PLIF could be an effective specific strategy to treat
PLIF-secreting breast cancers.
In the current study, we introduce the novel molecule C24D,
designed and synthesized as a PLIF antagonist. We show that C24D
polypeptide competitively inhibits the binding of C48-PLIF to T
cells. Anti-tumor cytotoxic T lymphocytes (CTLs) were generated
from naïve human lymphocytes treated with C24D and stimulated
in vitro with allogeneic whole non-manipulated MCF-7 and T47D
tumor cells. On reactivation with their targets, all CTL lines secreted
high levels of interferon-γ (IFN-γ) and induced tumor cell apoptosis.
Furthermore, we demonstrated in vivo that C24D treatment
inhibited the growth of MCF-7 tumors engrafted in nude mice
that were immune-compromised with naïve human PBMCs.
Our accumulated data indicate that C24D may represent a novel
strategy in breast cancer treatment through breakdown of the
immune tolerance common in tumor diseases.
Methods
C24D Polypeptide and Recombinant C48 Protein
C24D polypeptide synthesis was performed by the fully automated
Applied Biosystems Peptide Synthesizer Model 433A. This was
arranged by special order according to a submitted amino acid
sequence and is of 99.5% purity.
Recombinant C48 protein was produced in Escherichia coli, as
previously described [12].
Cells and Antibodies
HD-MAR T cell line established from a patient with Hodgkin’s
lymphoma [1] was kindly provided by Hanna Ben-Bassat (The
Hebrew University Hadassah Medical School, Jerusalem, Israel).
HD-MAR cells were grown and maintained in RPMI 1640
supplemented with 10% fetal calf serum and antibiotics. The
human breast cancer cell lines employed were obtained from
American Type Culture Collection (Rockville, MA). MCF-7,
T47D, and MDA-MB-231 human breast cancer cell lines were
maintained in monolayer cultures in fetal calf serum and antibiotics.
For passages, confluent monolayer cultures were trypsinized with
trypsin-EDTA solution (0.25% and 0.05%, respectively), washed
once, and seeded in culture medium.
PBMCs were isolated from blood buffy coats obtained from non-
identified blood bank donors supplied by MDA Blood Bank
(Tel Hashomer, Israel) and were approved by the local ethics
committee of Beilinson Medical Center (Petah Tikva, Israel). Buffy
coats were layered onto Lymphoprep solution (Nycomed, Oslo,
Norway) and spun at 2000 rpm for 20 minutes. The interface layer
was collected, washed twice, counted, and resuspended in phosphate-
buffered saline (PBS, pH 7.4) to the desired cell concentration.
Anti-C24D Igwas prepared by immunizing outbredmice withC24D
polypeptide in PBS mixed with complete Freund’s adjuvant at 1:1 ratio
(vol/vol), on days 1, 7, and 21. The mice were bled on day 28 and Igs
were isolated by salt precipitation. Anti-C48 mAb was prepared, as
previously described [9]. This mAb reacted with C48-PLIF but did not
cross-react with C24D. Anti-CD3 mAb (OKT3) was purchased from
Ortho Biotech Inc (Horsham, PA). phycoerythrin (PE)–anti-CD14+,
fluorescein isothiocyanate (FITC)–anti-CD4+ and PE–anti-CD8+ were
purchased from Becton Dickinson (San Jose, CA). FITC–anti-mouse
IgG was purchased from Dako (Carpinteria, CA).
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Flow Cytometry
For C48 and C24D binding experiments, HD-MAR T cells were
incubated with C48, C24D or both for 20 minutes under 5% CO2,
at room temperature, and 90% humidity, followed by two washes
with PBS containing 1% BSA and 0.05% sodium azide. The cells
were then incubated for 20 minutes on ice with anti-C48 mouse mAb
or mouse anti-C24 IgG followed by two washes, as above. After
incubation with FITC–anti-mouse IgG for 20 minutes on ice, the
cells were washed twice with PBS containing 0.05% sodium azide and
analyzed with a BD flow cytometer.
Breast Cancer Cells and PBMC Co-Cultures In Vitro for
Primary Activation
MCF-7 or T47D cells were transferred to RPMI 1640 and human
AB serum (10%). PBMCs (1 × 106) were added to MCF-7 or T47D
(0.1 × 106) at an effector/target (E:T) ratio of 10:1, followed by
treatment with C24D (30 μg/ml) at 0, 24, and 48 hours. The cell co-
cultures without C24D treatment served as a control. The cultures
were subjected to microscopic evaluation on days 5 and 7 of the
experiment.
Development of Specific Anti–Breast Cancer CTLs
On day 7 of co-culture, the medium was replaced by fresh RPMI
1640 containing 10% human AB serum and IL-2 (5 ng/ml). This
growth medium of the cultures was refreshed three times a week. The
lymphocytes were harvested after 4 weeks for further studies.
Tumor Cell Cytotoxicity Assays
Alamar Blue assay for quantitative analysis of cell viability was
performed, as previously described [24]. In brief, Alamar Blue was
directly added to culture medium. At various time intervals, the redox
reaction in which Alamar Blue was reduced by the cells was measured
by absorbance readings at 540 and 630 nm.
Methylthiazolyldiphenyl-tetrazolium bromide (MTT) reduction,
which is an indicator of cellular metabolic activity, was measured as
previously described [25]. In brief, breast cancer cells were incubated
for 5 hours with lymphocytes at different E:T ratios. After incubation
for 3 hours, 50 μl of 0.25% (wt/vol) solution of MTT in PBS was
added and further incubated for 2 hours. The non-adherent cells were
removed and the remaining adherent tumor cells were dissolved in a
mixture of DMSO (Sigma-Aldrich, Rehovot, Israel), 5% (wt/vol)
sodium dodecyl sulfate and 1% (vol/vol) 1 N hydrochloric acid. The
absorption at 570/650 nm was measured with a plate reader
(FLUOstar; BMG LABTECH, Offenburg, Germany).
Data Analysis
Cell viability was calculated with regard to the untreated breast
cancer cultures alone (control) [y0], which was set at 100% viability. A
lysis control [y100], wherein the cells were treated with 0.5% Triton
X-100, was set at 0% viability. This was found to be sufficient to
induce 100% cell death. Mean values from eight wells were
determined [25].
Annexin V Test for Apoptosis
Apoptotic cell death of breast cancer cells was performed using
Annexin V–based apoptosis kit [26]. In brief, 5 × 105 tumor cells were
mixed with 1.7 × 105 CTLs (E:T ratio of 1:3) in 0.4 ml of RPMI 1640
containing 10% human AB serum at various time periods. The cells
were further reacted with FITC–Annexin V and propidium iodide,using the Annexin V Apoptosis Detection Kit FITC (eBioscience,
San Diego, CA), according to the manufacturer’s instructions.
Gating of tumor cells from CTL–tumor cell mixture for apoptosis
analysis was first determined using anti-CD3 staining of the culture.
Negatively stained large cells were gated as tumor cell population. We
noticed that the same gating pattern was obtained with light-scatter
analysis of the culture and so we used this latter assay in our further
experiments for determination of tumor population. The percentage
of FITC-conjugated Annexin V–positive cells was analyzed by flow
cytometry (Becton Dickinson).
Quantitative image-based apoptotic index measurement using
multispectral imaging flow cytometry was acquired on the Image-
Stream multispectral imaging flow cytometer (Amnis Corporation,
Seattle, WA) [27].
Cytokine Production Evaluation
ELISA kits for the human cytokines IFN-γ and tumor necrosis
factor–α (TNF-α) were purchased from R&D Systems Incorporation
(Minneapolis, MN). These kits were used according to the
manufacturer’s instructions to quantify the indicated cytokine
production in the supernatants harvested from CTLs and target
tumor cell mixed cultures at different time periods.
In Vivo Studies
Athymic BALB/c nude mice were purchased from Harlan
(Rehovot, Israel). The mice were housed in a barrier facility. All
procedures were approved by the Institutional Animal Care
Committee of Tel Aviv University (Tel Aviv, Israel). The mice
were inoculated subcutaneously with MCF-7 human breast cancer
cells (5 × 106), in the presence of an estrogen source (slow release 60-
day estrogen pellets, 0.72 mg). Human PBMCs (50 × 106/0.5 ml
PBS) were injected intravenously after transplantation of MCF-7
tumor cells, as previously described [23]. In part of the groups,
mice did not receive PBMCs to assess direct effect of C24D on
tumor growth.
Treatment of Tumor-Bearing Mice with C24D
In each experiment, mice were divided into groups of five. C24D
dissolved in PBS (pH 7.2) was injected intraperitoneally to each
mouse daily, at an optimal dose of 60 μg/0.2 ml. Control mice
received daily injections of PBS.
Gross and Microscopic Pathology
Tumors were excised, measured and fixed in phosphate-buffered
formalin (pH 7.0). The paraffin-embedded blocks, tissue sections
and immunohistochemistry staining were performed by the
Department of Pathology, Rabin Medical Center (Petah Tikva,
Israel). For immunohistochemical staining, slides were incubated
with anti-LCA primary antibodies (BioGenex, Fremont, CA) at
previously determined optimal concentrations and developed with a
biotinylated secondary antibody, followed by conjugated streptavi-
din-peroxidase (Zymed Laboratories, San Francisco, CA), according
to the manufacturer’s instructions. The stained slides were
counterstained with Mayer’s Hematoxylin and Eosin (H&E) and
mounted with aqueous mounting solution.
Statistical Analysis
Results were presented as means ± SD. Comparisons were made by
Student's t test. A P value of less than or equal to .05 was considered
statistically significant.
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The C24D Molecule
C24D is a dimer of identical polypeptide chains cross-linked at the
N-terminal end with the amino acid cysteine followed by amino acids
homologous to amino acids 25 to 48 at the C-terminus of C48
protein [12]. The molecular weight of the synthetic C24D molecule
is 6418.8 with 99.5% purity.
C24D Binds to Human T Cells (HD-MAR) and Competitively
Inhibits the Binding of C48-PLIF
HD-MAR is a human T cell line (CD3+, CD4−, CD8−) that
constitutively binds PLIF [28,29]. FACS analysis using anti-C24D and
anti-C48 antibodies revealed the binding of both C24D and C48 to the
surface of human HD-MAR cells (Figure 1, A, B, E and F). Yet, C24D
inhibited the binding of C48 to HD-MAR cells in a concentration-
dependent manner (Figure 1, C, D and F). This was demonstrated by
the significant lowerMean Fluorescence Intensity (MFI)measuredwhen
HD-MAR cells were preincubated with C24D for 20 minutes at room
temperature and then with C48, compared to cells without C24D
(Figure 1F). These results indicate that C24D compete with C48 in
binding to HD-MAR cells and thus inhibits C48-PLIF subsequent
binding. It is worthmentioning that althoughC24Dbinds toHD-MAR
cells and compete with C48 and PLIF binding, it does not exert their
immunomodulatory activity (data not shown). Thus, C24D mayFigure 1. C24D inhibits the binding of C48-PLIF protein to T lymphocyt
(A) and C48 (B) to HD-MAR T cells detected by anti-C24D IgG and anti-
0.2 μg per sample of C24D (C). C48 binding to HD-MAR cells is inhib
demonstrated as MFI value ± SD (n = 3) of C24D binding (E) and birepresent a competitive inhibitor for PLIF in its biologic systems. This
prompted our attempts to investigate whether C24Dwould break up the
PLIF-induced immune suppression in anti–breast cancer immunity.
C24D Treatment of PBMCs Cultured with MCF-7 and T47D
Human Breast Cancer Cells Resulted in Activation of Specific
Anti-Tumor CTLs
A schematic outline for the use of C24D to develop anti–breast
cancer immune response and specificCTLs fromPBMCs of blood bank
donors is portrayed in Figure 2A.MCF-7 andT47D tumor cells grow as
a monolayer in tissue culture plates. We found that the addition of
PBMCs to tumor cell cultures at a ratio of 10:1 for 7 days did not affect
their growth.However, the addition of C24D to the cultures resulted in
tumor cell lysis. An example of a microscopic view is shown for MCF-7
and PBMC co-cultures (Figure 2, B and C). It is noteworthy that
C24Ddid not bind to the tumor cells. It had no direct anti-tumor effect
when added to the tumor cell cultures without PBMCs (not shown).
Using the Alamar Blue assay for quantitative analysis of tumor cell
viability, it was evident that 25% to 35%of the tumor cells were lysed in
both T47D and MCF-7 tumor-PBMC co-cultures treated with C24D
but not in the untreated cultures (Figure 2D). Furthermore, PBMCs
remained adherent in the lytic areas of the C24D-treated co-cultures
(Figure 2C). The adherent PBMC-derived cells were identified as
CD3+ and CD14+ cell types (not shown). Furthermore, cells cultured
for 4 weeks in IL-2 supplemented growthmedium yielded six lymphoides. Representative histograms for FACS analysis of binding of C24D
C48 mAb, respectively. C48 binding to HD-MAR cells is inhibited by
ited by 1 μg per sample of C24D (D). The above results are further
nding of C48 to HD-MAR cells and its inhibition by C24D (F).
Figure 2. In vitro development of anti-tumor cytotoxic T cells following C24D treatment. (A) A schematic illustration describing the basic
concept of this study, i.e., blocking C48-PLIF by C24D on T cells results in the development of specific anti-tumor CTLs. The two stages of
the experiments are exhibited: In primary cultures, human PBMCs are co-cultured with human breast cancer cell lines at an E:T ratio of
10:1. The mixed cultures are either untreated (control) or treated with C24D at 0, 24 and 48 hours and incubated for 7 days. The culture
medium is replaced on day 7 with growth medium supplemented with human IL-2. The cultures are further incubated for 4 weeks
and harvested. Highly cytotoxic cells were obtained from PBMCs incubated with tumor cells in presence of C24D. In contrast, there is
no anti-tumor cytotoxic activity from PBMCs incubated with tumor cells without C24D. (B and C) Giemsa staining of MCF-7 tumor cells
co-cultured for 7 dayswith control PBMCs (B) or with C24D-treated PBMCs (C). (D) Alamar Blue cytotoxicity assay performed on day 7 on
MCF-7 and T47D tumor cells cultured with their respective control or C24D-treated PBMCs (E:T ratio of 10:1). Histograms represent
mean value ± SD (n= 6). (E) Flow cytometry analysis of T cells in secondary culture shows a predominance of CD8+ over CD4+ T cells.
PBMCs from three different donors are presented.
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T47D human breast cancer cells. FACS analyses revealed that the
majority cells of the six harvested C24D-treated lymphocyte lines were
CD8+ (Figure 2E). A low yield of lymphocytes was harvested from the
control (C24D–untreated tumor–PBMC co-cultures), which were
mostly CD4+ (not shown). It is noteworthy that no residual tumor cells
were recovered from the harvested lymphocyte cultures.
Anti–MCF-7 and Anti-T47D CTLs Are Highly Cytotoxic and
Tumor Type Restricted
Successful experimental cancer immunotherapy requires represen-
tative cell lines that can be used as target cells for vaccines and
verification of the efficacy of activated CTLs. Cytotoxic T cells
recognize short peptide sequences presented by the HLA class I
molecules on the tumor cell surface [30]. MCF-7 and T47D breast
cancer cells, although share at least seven identified tumor antigens,
have different HLA class I molecules and thus expected to induce
non–cross-reactive CTL clones [31].In a microscopic view, we showed that the PBMCs pre-activated
with whole tumor cells without C24D (control) did not affect their
target cells (Figure 3, A and D). In contrast, following C24D
treatment, the cytolytic activity of CTLs raised against each of MCF-
7 (Figure 3B) and T47D (Figure 3E) cell lines was tumor target
restricted and not cross-reactive with the other cell line (Figure 3, C
and F). These CTLs were highly cytotoxic to their specific target
cells, leading to cytolysis of up to 90% of the corresponding tumor
cells at E:T ratios of 1:1 after a 5-hour incubation (Figure 3, G
and H).
Anti–MCF-7 and Anti-T47D CTLs Secrete High Levels of
IFN-γ and Induce Apoptosis of Tumor Cells on Reactivation
with Their Respective Target Cells
When anti–MCF-7 and anti-T47D CTLs were reactivated for
5 hours with their corresponding cancer cells, they secreted increasing
levels of IFN-γ proportional to the number of effector cells (Figure 4,
A and B). In contrast, secretion was not detected when CTLs were
Figure 3. C24D-induced CTLs are highly cytotoxic to their specific tumor cells. (A–F) Representative light microscopy images of MCF-7
and T47D tumor cells co-cultured for 5 hours with control T lymphocytes or induced CTLs. (G and H) E:T cell ratio–dependent cytotoxicity
detected by MTT cytotoxicity assay (5-hour incubation). Data represent mean value ± SD (n = 3).
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cell line. Furthermore, the high levels of IFN-γ secreted by the CTLs
increased following extension of reactivation time, still in a tumor-
target specific manner (Figure 4C). The cytokine secretion was
accompanied by enhanced apoptotic death of MCF-7 and T47D
tumor cells co-cultured with their respective CTLs (Figure 4,D and E).
Apoptosis determined by FACS analysis of Annexin V and PI-labeled
cells showed that anti–MCF-7CTLs (Figure 4D) and anti-T47DCTLs
(Figure 4E) induced target cell–specific apoptosis. The above data
indicate the functional restriction and specificity of the C24D-
developed CTLs.Anti–MCF-7 CTLs Are Cross-Cytotoxic to the MDA-MB-231
Cell Line
To examine whether the lack of cross-reactivity between anti–
MCF-7 and anti-T47D CTLs is referred to HLA-A type
incompatibility, we tested the ability of anti–MCF-7 CTLs to
react against MDA-MB-231, a breast cancer cell line that share the
same HLA-A type with MCF-7 (HLA-A*0201). MDA-MB-231
(HLA-A*0201) is a triple-negative breast cancer (TNBC), an
aggressive breast cancer subtype, not expressing estrogen receptor,
progesterone receptor, and HER2/neu that represents a major
clinical challenge [32].
Figure 4. Activated CTLs secrete IFN-γ and initiate apoptosis of their specific targets. (A and B) IFN-γ concentrations in the supernatants
obtained from 5-hour co-cultures of MCF-7 and T47D tumor cells with increasing CTL ratios (0.5:1 and 1:1). (A) Anti–MCF-7 CTLs. (B) Anti-
T47D CTLs. (C) IFN-γ secreted by anti–MCF-7 CTLs and anti-T47D CTLs (E:T ratio of 1:1) determined after extended incubation (24 hours).
All values are expressed as mean ± SD (n = 3). (D and E) Enhanced apoptotic death of MCF-7 and T47D tumor cells co-cultured with
(D) anti–MCF-7 CTLs or (E) anti-T47D CTLs determined by FACS analysis (Annexin V and PI labeling).
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presented in a representative microscopic view (Figure 5A). We observe
major lysis of MDA-MB-231 TNBC cells with the anti–MCF-7 CTLs
(Figure 5A, upper) but not with the anti-T47DCTLs (Figure 5A, lower).
In a multispectral imaging flow cytometry, we measured the
apoptosis of MDA-MB-231 cells stained with FITC–Annexin V
(green) and PI (red) following reactivity with anti–MCF-7 CTLs at
an E:T ratio of 1:1 (Figure 5B). The increasing rate of early (Annexin
V+) and late (PI+) apoptosis is demonstrated in a quantitative time
course (up to 5 hours) of an image-based apoptotic index (Figure 5C).
It is noteworthy that no apoptosis was demonstrated with anti-T47D
CTLs cross-activated with MDA-MB-231 (not shown). Further-
more, anti–MCF-7 CTLs exhibited broad reactivity against MDA-
MB-231 and MCF-7 target cells in TNF-α and IFN-γ assays.
Comparative time course measurements at incubations of 3 and
5 hours revealed the secretion of both TNF-α (Figure 5D) and IFN-γ
(Figure 5E) by anti–MCF-7 CTLs reactivated with MDA-MB-231
TNBC. It is noteworthy that when anti–MCF-7 CTLs were
reactivated with MDA-MB-231 tumor cells, both IFN-γ and
TNF-α cytokines were secreted earlier and at significantly higher
levels compared to the reactivation of their specific target MCF-7 cells
(Figure 5, D and E). Anti-T47D CTLs did not secrete TNF-α or
IFN-γ upon reaction with MDA-MB-231 due to HLA-A restriction,
as expected (Figure 5, D and E).Therapeutic Effect of C24D on MCF-7 Tumor Growth in
Nude Mice
The in vitro effect of C24D treatment on the development of anti–
MCF-7 CTLs documented above motivated us to investigate whether
in vivo C24D treatment of human PBMCs reconstituted, tumor-
bearing nude mice would affect the MCF-7 tumor growth. Nude
mice were engrafted subcutaneously with MCF-7 tumor cells,
transfused with human PBMCs, and treated by daily intraperitoneal
injections of either C24D or PBS for 19 days. C24D treatment did
not affect the mouse weight compared to the PBS-treated control
group (Figure 6A) but markedly inhibited the tumor growth (P =
.017; Figure 6, B and C). The stability of mice body weight in both
groups along the experiment indicated lack of toxicity of C24D.
It is worth mentioning that C24D treatment of nude mice bearing
MCF-7, without PBMC inoculation, did not influence tumor size
compared to control PBS treatment (tumor size of 180 ± 27 cm and
164 ± 19 cm, respectively, P N .5, n = 4).
Histochemical analyses of representative tumors derived from
PBMCs reconstituted immune-compromised mice treated with
C24D exhibited a large area of tumor necrosis (Figure 6D, upper
right), compared to minimal or no necrosis in the corresponding
control mice (Figure 6D, upper left). Further, immunohistochemical
staining with anti-CD45+ antibodies was performed. Images
obtained from the representative tumors are shown in Figure 6D
Figure 5. Anti–MCF-7 CTLs cross-activated by HLA-A2+ MDA-BM-231 cells induced target cell apoptosis and TNF-α and IFN-γ secretion.
(A) Representative light microscopy images of MDA-MB-231 tumor cells co-cultured for 7 hours with anti–MCF-7 CTLs or anti-T47D CTLs.
(B) Stages of apoptotic death of MDA-MB-231 tumor cells co-cultured for 5 hours with anti–MCF-7 CTLs, determined by imaging flow
cytometry: lower left—viable cells; lower right—early apoptosis; upper right—late apoptosis; upper left—dead cells (Annexin V and PI
labeling). (C) Representative time course development of early and late apoptosis of MDA-MB-231 tumor cells by anti–MCF-7 CTLs.
(D and E) Cytokine concentrations in the supernatants obtained from co-cultures of MDA-MB-231 andMCF-7 tumor cells with anti–MCF-7
CTLs or anti-T47D CTLs at 3 hours and 5 hours for (D) TNF-α and (E) IFN-γ. All values are expressed as mean ± SD (n = 3).
748 Novel C24D Synthetic Polypeptide Solodeev et al. Neoplasia Vol. 16, No. 9, 2014(lower). The specimen obtained from the C24D-treated group
exhibited massive necrotic areas with intra-tumor infiltration of
human CD45+ cells (Figure 6D, lower right, brown staining),
compared to lack of CD45+ cells in the PBS-treated specimen
(Figure 6D, lower left). It is therefore concluded that in vivo
treatment of PBMC reconstituted mice with C24D enables anti–
MCF-7 vaccination resulting in tumor growth inhibition.
Discussion
The unique aspect of this study is the finding that C24D is a novel
PLIF-specific binding antagonist to T cells. C24D is able to break the
in vitro and in vivo immune tolerance induced by PLIF-producing
human breast cancer cells, resulting in tumor cell apoptosis and
growth inhibition. Without blocking PLIF activity, no anti-tumor
activation or tumor growth inhibition developed, indicating the
major role of PLIF in the suppression of the anti-tumor immune
response. It is worth mentioning here that C24D does not exert any
direct anti-tumor effect.
We demonstrate here that tumor-specific CTLs were generated from
PBMCs stimulated with, whole non-manipulated allogeneic, MCF-7
and T47D tumor cells only following treatment with C24D.
Depending on the stimulator cell line, highly reactive CTL lines were
developed from each donor. This specificity was reflected by the factthat CTLs raised against MCF-7 failed to react against T47D cells that
differ in HLA-A haplotype but strongly reacted against MDA-MB-231
cells that share the same HLA-A haplotype with MCF-7 cells.
The CTL lines (CD8+) generated in the C24D-treated co-cultures
secreted high levels of IFN-γ and TNF-α on reactivation with the
corresponding tumor target. IFN-γ regulates various biologic
programs that could participate in abrogating tumor growth
[33,34]. One of the important anti-tumor mechanisms induced by
IFN-γ is its capacity to inhibit cellular proliferation [35–37] and
promote apoptosis.
Our results indicate that the therapeutic potential of C24D in tumor
immune therapy is applicable in direct treatment of breast cancer–
bearing patients leading to braking of PLIF-related immune suppres-
sion.Moreover, C24D is also applicable in allogeneic whole tumor cell–
based vaccination strategies for the induction of anti-tumor immunity
in cases of weak immunogenic tumors [38–41]. Actually, our results
support these notions since wholeMCF-7 tumor cells as a vaccine in the
C24D-induced T cell activation resulted in high reactivity against the
MCF-7 cells itself as well as against other breast cancer cell line sharing
matched HLA-A haplotype with MCF-7 cells (i.e., MDA-MB-231).
PLIF, a physiological pregnancy-related protein, is upregulated and
secreted by other malignant diseases [42] and in human immuno-
deficiency virus infection [43]. PLIF exerts its antigen-specific
Figure 6. In vivo C24D treatment inhibits MCF-7 tumor growth in human PBMC transfused nude mice. (A–D) Immune-compromised nude
mice engrafted with MCF-7 tumor cells were treated with C24D or PBS (control) for 18 days (five mice in each group). (A) Mean value of
mice weight ± SD. (B) Mean volumes ± SD of tumors removed on day 19. (C) Photographs of removed tumors. (D) H&E staining (top
panels) and anti-CD45+ staining (bottom panels) of tumor sections. CD45+ cell infiltration (stained brown, right bottom panel) is exhibited
only in the tumor removed from C24D-treated mice. No infiltration of CD45+ cells was seen in the tumor removed from control mice (left
bottom panel).
Neoplasia Vol. 16, No. 9, 2014 Novel C24D Synthetic Polypeptide Solodeev et al. 749immune suppression by binding only to the activated T cells [12–14].
In previous studies, we demonstrated that human C48-PLIF is an
effective therapeutic immune suppressive agent enabling allogeneic
non-manipulated murine bone marrow transplantation yielding long-
lasting donor-specific immune tolerance [44]. In contrast, this study
demonstrates that C24D competitively inhibit PLIF binding to T
cells and restores T cell immunity, resulting in rejection of breast
cancer cells.
To validate any vaccination strategy, it is important to define the
most appropriate population for testing the vaccine and to determine
the optimal combination with other existing therapies. The greatest
expectations for cancer vaccines consider the use of immunotherapy
in patients whose immune system and E:T ratio are favorable. To
optimize the C24D activity and address questions regarding optimal
treatment schedules, PLIF is an effective biomarker for diagnosis and
follow-up in patients with breast cancer [11,45–48].
Conclusion
The current findings support our strategy to modulate PLIF-induced
tumor-immune suppression by the novel C24D molecule and
produce an anti–breast cancer vaccination in adoptive and active
breast cancer immunotherapy.References
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